Skip to main content
SpringerLink
Log in

Basic Aspects of Calcitonin in Skeletal Health

  • Chapter
Osteoporosis

Part of the book series: Contemporary Endocrinology ((COE))

  • 341 Accesses

Abstract

Calcitonin (CT) is a 32-aminoacid peptide that is secreted by thyroidal C cells in mammals and by the ultimobranchial gland in submammals. CT, that was originally identified as a hypocalcemic factor present in bovine serum (1) exerts its hypocalcemic effects primarily by directly inhibiting osteoclastic bone resorption (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Copp DH, Cameron EC, Cheney BA, et al. Evidence for calcitonin — a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962; 70: 638–649.

    Article  PubMed  CAS  Google Scholar 

  2. Nicholson GC, Moseley JM, Sexton PM, et al. Abundant calcitonin receptors in isolated rat osteoclasts: biochemical and autoradiographic characterization. J Clin Invest 1986; 78: 355–360.

    Article  PubMed  CAS  Google Scholar 

  3. Potts JT. Chemistry of the calcitonins. Bone Miner 1992; 16: 169–173.

    Article  PubMed  CAS  Google Scholar 

  4. Segre GV, Goldring SR. Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagon-like peptide, growth hormone-releasing hormone, and glucagon belong a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 1993; 4: 309–314.

    Article  PubMed  CAS  Google Scholar 

  5. Muff R, Born W, Fischer JA. Calcitonin, calcitonin gene-related peptide, adrenomedullin and amylin: homologous peptides, separate receptors and overlapping biological actions. Eur J Endocrino11995; I33: 17–20.

    Google Scholar 

  6. Poyner DR. Molecular pharmacology of receptors for calcitonin-gene-related peptide, amylin and adrenomedullin. Biochem Soc Trans 1997; 25: 1032–1036.

    PubMed  CAS  Google Scholar 

  7. Cornish J, Callon KE, Lin CQX, et al. Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J Bone Miner Res 1999; 14: 1302–1309.

    Article  PubMed  CAS  Google Scholar 

  8. Amara SG, Jonas V, Rosenfeld MG. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982; 298: 240–244.

    Article  PubMed  CAS  Google Scholar 

  9. Rosenfeld MG, Amara SG, Evans RM. Alternative RNA processing: determining neuronal phenotype. Science 1984; 225: 1315–1320.

    Article  PubMed  CAS  Google Scholar 

  10. Benett MM, Amara SG. Molecular mechanisms of cell-specific and regulated expression of the calcitonin/a-CGRP and b-CGRP genes. Ann New York Acad Sci 1993; 257: 36–49.

    Google Scholar 

  11. Roos BA, Fischer JA, Pignat W, et al. Evaluation of the in vivo and in vitro calcium-regulating actions of non calcitonin peptides produced via calcitonin gene expression. Endocrinology 1986; 118: 46–51.

    Article  PubMed  CAS  Google Scholar 

  12. Lundberg JM, Franco Cereceda A, Hua X, et al. Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol 1985; 108: 315–319.

    Article  PubMed  CAS  Google Scholar 

  13. Tschopp FA, Henke H, Petermann JB, et al. Calcitonin gene-related peptide and its binding sites in the human central nervous system and pituitary. Proc Natl Acad Sci USA 1985; 82: 248–252.

    Article  PubMed  CAS  Google Scholar 

  14. Ho Soi J, Murray GF, Egan CL, et al. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 1993; 363: 159–163.

    Article  Google Scholar 

  15. Uchida S, Yamamoto H, Iio S, et al. Release of calcitonin gene-related peptide-like immunoreactive substance from neuromuscular junction by nerve excitation and its action on striated muscle. J Neurochem 1990; 54: 1000–1003.

    Article  PubMed  CAS  Google Scholar 

  16. Brain SD, MacIntyre I, Williams TJ. A second form of human calcitonin gene-related peptide which is a potent vasodilator: Eur J Pharmacol 1986; 124: 349–352.

    Article  PubMed  CAS  Google Scholar 

  17. Gennari C, Fischer JA. Cardiovascular action of calcitonin gene-related peptide in humans. Calcif. Tissue Int. 1985: 37: 581–584.

    Article  PubMed  CAS  Google Scholar 

  18. Goltzman D, Mitchell J. Interaction of calcitonin and calcitonin gene-related peptide at receptor sites in target tissues. Science 1985: 227: 1343–1345.

    Article  PubMed  CAS  Google Scholar 

  19. Shih C, Bernard GW. Calcitonin gene-related peptide enhances bone colony development in vitro. Clin Orthop Rel Res 1997; 334: 335–344.

    Google Scholar 

  20. Sexton PM. Central nervous system binding sites for calcitonin and calcitonin gene related peptide. Molecular Neurobiology 1991; 5: 251–273.

    Article  PubMed  CAS  Google Scholar 

  21. Gorn AH, Rudolph SM, Flannery MR, et al. Expression of two human skeletal calcitonin receptors isoforms cloned from a giant cell tumour of bone. J Clin Invest 1995; 95: 2680–2691.

    Article  PubMed  CAS  Google Scholar 

  22. Albrandt K, Brady EMG, Moore CX, et al. Molecular cloning and functional expression of a third isoform of the human calcitonin receptor and partial characterization of the calcitonin receptor gene. Endocrinology 1995; 136: 5377–5384.

    Article  PubMed  CAS  Google Scholar 

  23. Gorn AH, Lin HY, Yamin M, et al. The cloning, characterization and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J Clin Invest 1992; 90: 1726–1735.

    Article  PubMed  CAS  Google Scholar 

  24. Kuestner RE, Elrod RD, Grant FJ, et al. Cloning and characterization of an abundant subtype of the human calcitonin receptor. Molecular Pharmacology 1994; 46: 246–255.

    PubMed  CAS  Google Scholar 

  25. Nakamura M, Zhang Z, Shan L, et al. Allelic variants of human calcitonin receptor in the Japanese population. Hum Genet 1997; 99: 38–41.

    Article  PubMed  CAS  Google Scholar 

  26. Masi L, Becherini L, Gennari L, et al. Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal italian women. Bioch Bioph Res Commun 1998; 245: 622–626.

    Article  CAS  Google Scholar 

  27. Masi L, Becherini L, Colli E, et al. Polymorphisms of the calcitonin receptor gene are associated with bone mineral density in postmenopausal italian women. Bioch Bioph Res Commun 1998; 248: 190–195.

    Article  CAS  Google Scholar 

  28. Taboulet J, Frenkian M, Frendo JL, et al. Calcitonin receptor polymorphism is associated with a decreased fracture risk in postmenopausal women. Hum Mol Genet 1998; 13: 2129–2133.

    Article  Google Scholar 

  29. Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983; 57: 819–825.

    Article  PubMed  CAS  Google Scholar 

  30. Zaidi M, Shankar VS, Huang CL-H, et al. Molecular mechanisms of calcitonin action. Endocrine Journal 1994; 2: 459–467.

    CAS  Google Scholar 

  31. Nicholson CG, Moseley JM, Sexton PM, et al. Abundant calcitonin receptors in isolated rat osteoclasts: biochemical and autoradiographic characterization. J Clin Invest 1986; 78: 355–360.

    Article  PubMed  CAS  Google Scholar 

  32. Moonga BS, Alam ASMT, Bevis PJR, et al. Regulation of cytosolic free calcium in isolated rat osteoclasts by calcitonin. J Endocrinol 1992; 132: 241–249.

    Article  PubMed  CAS  Google Scholar 

  33. Su Y, Chakarborty M, Nathanson M, Baron R. Differential effects of the 3’,5’-cyclic adenosyne monophosphate and protein kinase C pathways on the response of isolated rat osteoclasts to calcitonin. Endocrinology 1992; 131: 1497–1502.

    Article  PubMed  CAS  Google Scholar 

  34. Stroop S, Thompson DL, Kuestner RE, et al. A recombinant human calcitonin receptor function as an extracellular calcium sensor. J Biol Chem 1993;268:19, 927–19, 930.

    Google Scholar 

  35. Takahashi S, Goldring S, Katz M, et al. Down regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 1995; 95: 167–171.

    Article  PubMed  CAS  Google Scholar 

  36. Rakopoulos M, Ikegame M, Findlay DM, et al. Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Bone 1995; 17: 447–453.

    Article  PubMed  CAS  Google Scholar 

  37. Wada S, Udafawa N, Akatsu T, et al. Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology 1997; 138: 521–529.

    Article  PubMed  CAS  Google Scholar 

  38. Wada S, Udagawa N, Nagata N, et al. Calcitonin receptor down-regulation relates to calcitonin resistance in mature mouse osteoclasts. Endocrinology 1996; 137: 1042–1048.

    Article  PubMed  CAS  Google Scholar 

  39. Inoue D, Shih C, Galson DL, et al. Calcitonin-dependent down-regulation of the mouse Cla calcitonin receptor in cells of the osteoclast lineage involves a transcriptional mechanism. Endocrinology 1999; 140: 1060–1068.

    Article  PubMed  CAS  Google Scholar 

  40. Parthermore JG, Deftos LJ. Secretion of calcitonin in primary hyperparathyroidism. J Clin Endocrinol Metab 1979; 49: 223–226.

    Article  Google Scholar 

  41. Cooper CW, Bolman RM, Linehan WM, et al. Interrelationships between calcium, calcemic hormones and gastrointestinal hormones. Rec Prog Horm Res 1978; 34: 259.

    PubMed  CAS  Google Scholar 

  42. Stevenson JC, Hillyard CJ, Mac Intyre I, et al. A physiological role for calcitonin: protection of the maternal skeleton. Lancet 1979; 2: 769–770.

    Article  PubMed  CAS  Google Scholar 

  43. Stevenson JC, Abeyasekera G, Hillyard CJ, et al. Calcitonin and the calcium-regulation hormones in psotmenopausal women: effect of oestrogens. Lancet 1981;i:693–695.

    Google Scholar 

  44. Azria M. The Calcitonins, Physiology and Pharmacology. Karger, Basel, 1989.

    Google Scholar 

  45. Kanis JA, Heynen G, Cundy T, et al. An estimate of the endogenous secretion rate of calcitonin in man. Clin Sci 1982; 63: 145–152.

    PubMed  CAS  Google Scholar 

  46. Deftos LJ, Weisman MH, Williams GW, et al. Influence of age and sex on plasma calcitonin in human beings. N Engl J Med 1980; 302: 1351–1353.

    Article  PubMed  CAS  Google Scholar 

  47. Silva OL, Becker KL. Immunoreactive calcitonin in extrathyroid tissues. In: Pecile A, ed. Calcitonin 1980. Excerpta Medica, Amsterdam, 1981, pp. 144–153.

    Google Scholar 

  48. Milhaud G. Ectopic secretion of calcitonin. In: Pecile A, ed. Calcitonin 1980. Pecile A, Excerpta Medica, Amsterdam, 1981, pp. 154–169.

    Google Scholar 

  49. Taggart HM, Chesnut CH, Ivey JL, et al. Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis? Lancet 1982; 1: 475–478.

    Article  PubMed  CAS  Google Scholar 

  50. Body JJ, Demeester-Mirkine N, Borkowski A, et al. Calcitonin deficiency in primary hypothyroidism. J Clin Endocrinol Metab 1986; 62: 700–703.

    Article  PubMed  CAS  Google Scholar 

  51. Foresta C, Busnardo B, Ruzza G, et al. Lower calcitonin levels in young hypogonadic men with osteoporosis. Horm Metab Res 1983; 15: 206–207.

    Article  PubMed  CAS  Google Scholar 

  52. Carey DE, Jones KL, Parthermore JG, et al. Calcitonin secretion in congenital nongoitrous cretinism. J Clin Invest 1980; 65: 892–895.

    Article  PubMed  CAS  Google Scholar 

  53. Owyang C, Heath H, Sizemore GW, et al. Comparison of the effects of pentagastrin and meal-stimulated gastrin on plasma calcitonin in normal man. Am J Dig Dis 1978; 23: 1084–1088.

    Article  PubMed  CAS  Google Scholar 

  54. Cohen SL, Mac Intyre I, Grahame-Smith D, et al. Alcohol-stimulated calcitonin release in medullary carcinoma of the thyroid. Lancet 1973; 1172, 1173.

    Google Scholar 

  55. Wells SA, Baylin SB, Linehan WM, et al. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 1978; 188: 139.

    Article  PubMed  Google Scholar 

  56. Morris HR, Panico M, Etienne T, et al. Isolation and characterization of human calcitonin gene-related peptide. Nature 1984; 308: 746–748.

    Article  PubMed  CAS  Google Scholar 

  57. Pearse AG, Polak JM. Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas. Gut 1971; 12: 783–788.

    Article  PubMed  CAS  Google Scholar 

  58. Silva OL, Becker KL, Primack A, et al. Ectopic secretion of calcitonin by oat-cell carcinoma. N Engl J Med 1974; 290: 1122–1124.

    Article  PubMed  CAS  Google Scholar 

  59. Coombes RC, Hillyard C, Greenberg PB, et al. Plasma immunoreactive calcitonin in patients with non-thyroid tumours. Lancet 1974; 1: 1080–1083.

    Article  PubMed  CAS  Google Scholar 

  60. Wallach SR, Royston I, Taetle R, et al. Plasma calcitonin as a marker of disease activity in patients with small cell carcinoma of the lung. J Clin Endocrinol Metab 1981; 53: 602–606.

    Article  PubMed  CAS  Google Scholar 

  61. Galante L, Joplin GF, Maclntyre I et al. The calcium lowering effect of synthetic human, porcine and salmon calcitonin in patients with Paget’s disease. Clin Sci 1973; 44: 605–610.

    PubMed  CAS  Google Scholar 

  62. Gennari C, Chierichetti SM, Vibelli C, et al. Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man. Curr Ther Res 1981; 30: 1024–1032.

    CAS  Google Scholar 

  63. Ardaillou R, Paillard F, Sraer J, et al. Compared kinetics of salmon and human radioiodinated calcitonins in man. Horm Metab Res 1973; 5: 232, 233.

    Google Scholar 

  64. Huwyler R, Born W, Ohnhaus EE, et al. Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man. Am J Physiol 1979; 236: E15–19.

    PubMed  CAS  Google Scholar 

  65. Overgaard K, Agnusdei D, Hansen MA, et al. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991; 72: 344–349.

    Article  PubMed  CAS  Google Scholar 

  66. Kurose H, Seino Y, Shima M et al. Intranasal absorption of salmon calcitonin. Calcif Tissue Int 1987; 41: 249–251.

    Article  PubMed  CAS  Google Scholar 

  67. Pun KK, Chan LW, Lau P et al. Absorption of intranasal salmon calcitonin in normal subjects and hypogonadic men. Calcif Tissue Int 1990; 46: 130–132.

    Article  PubMed  CAS  Google Scholar 

  68. Thamsborg G, Storm TL, Brinch E et al. The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium. Calcif Tissue Int 1990; 46: 5–8.

    Article  PubMed  CAS  Google Scholar 

  69. Buclin T, Randin JP, Jacquet AF et al. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 1987; 41: 252–258.

    Article  PubMed  CAS  Google Scholar 

  70. Reginster JY, Denis D, Albert A. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone Miner 1987; 2: 133–140.

    PubMed  CAS  Google Scholar 

  71. Gennari C. Salmon calcitonin (Mialcic) nasal spray in prevention and treatment of osteoporosis. Clin Rheumatol 1989; 8: S61–65.

    Article  Google Scholar 

  72. Thamsborg G, Skousgaard SG, Daugaard H et al. Acute effects of nasal salmon calcitonin on calcium and bone metabolism. Calcif Tissue Int 1993; 53: 232–236.

    Article  PubMed  CAS  Google Scholar 

  73. Fiore CE, Romagnoli A, Foti R et al. Assessment of the biological activity of synthetic salmon calcitonin by intranasal administration in healthy volunteers. Drugs Exp Clin Res 1991; 17: 537–542.

    PubMed  CAS  Google Scholar 

  74. Abbiati G, Arrigoni M, Frignani S et al. Effect of salmon calcitonin on deoxypyridinoline (Dpyr) urinary excretion in healthy volunteers. Calcif Tissue Int 1994; 55: 346–348.

    Article  PubMed  CAS  Google Scholar 

  75. Overgaard K, Christiansen C. A new biochemical markers of bone resorption for follow-up on treatment with nasal salmon calcitonin. Calcif. Tissue Int 1996; 59: 12–16.

    Article  PubMed  CAS  Google Scholar 

  76. Kraenzlin ME, Seibel MJ, Trechsel U, et al. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 1996; 58: 216–220.

    PubMed  CAS  Google Scholar 

  77. Wener JA, Gorton SJ, Raisz LG. Escape from inhibition of resorption in cultures of fetal bone treated with calcitonin and parathyroid hormone. Endocrinology 1972; 90: 752–759.

    Article  PubMed  CAS  Google Scholar 

  78. Tashjian AH, Wright DR, Ivey JL, et al. Calcitonin binding sites in bone: relationship to biological response and “escape”. Recent Prog Horm Res 1978; 34: 285–334.

    PubMed  CAS  Google Scholar 

  79. Reginster JY, Gennari C, Mautalen C, et al. Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget’s disease of bone. Scand J Rheumatol 1990; 19: 83–86.

    Article  PubMed  CAS  Google Scholar 

  80. Bouizar Z, Rostene WH, Milhaud G. Down regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc Natl Acad Sci USA 1987; 84: 5125–5128.

    Article  PubMed  CAS  Google Scholar 

  81. Overgaard K, Hansen MA, Herss Nielsen VA, et al. Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment. Am J Med 1990; 89: 1–6.

    Article  PubMed  CAS  Google Scholar 

  82. Gennari C, Agnusdei D, Montagnani M, et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992; 50: 381–383.

    Article  PubMed  CAS  Google Scholar 

  83. Wallach S, Rousseau G, Martin L, et al. Effects of calcitonin on animal and in vitro models of skeletal metabolism. Bone 1999; 25: 509–516.

    Article  PubMed  CAS  Google Scholar 

  84. Karachalios T, Lyritis GP, Giannarakos DG, et al. Calcitonin effects on rabbit bone. Bending tests on ulnar osteotomies. Acta Orthop Scand 1992; 63: 615–618.

    PubMed  CAS  Google Scholar 

  85. Mosekilde L, Danielsen CC, Gasser J. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone (1–38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology 1994; 134: 2126–2134.

    Article  PubMed  CAS  Google Scholar 

  86. Geusens P, Boonen S, Nijs J, et al. Effect of calcitonin on femoral bone quality in adult ovariectomized ewes. Calcif Tissue Int 1996; 59: 315–320.

    Article  PubMed  CAS  Google Scholar 

  87. Cornish J, Callon KE, Cooper GJS, et al. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun 1995; 207: 133–139.

    Article  PubMed  CAS  Google Scholar 

  88. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363–1374.

    Article  PubMed  CAS  Google Scholar 

  89. Guillemin R. The endocrinology of the neuron and the neural origin of endocrine cells. Neurosci Res Prog Bull 1978; 16: 1–25.

    Google Scholar 

  90. Pavlinac DM, Lenhard LW, Parthermore JG, et al. Immunoreactive calcitonin in human cerebrospinal fluid. J Clin Endocrinol Metab 1980; 50: 717–720.

    Article  PubMed  CAS  Google Scholar 

  91. Deftos LJ, Burton D, Bone HG, et al Immunoreactive calcitonin in the intermediate lobe of the pituitary. Life Sci 1978; 23: 743–748.

    Article  PubMed  CAS  Google Scholar 

  92. Olgiati V, Guidobono F, Netti C, et al. Localization of calcitonin binding sites in rat central nervous system: evidence of its neuroactivity. Brain res 1983; 265: 209–215.

    Article  PubMed  CAS  Google Scholar 

  93. Maurer R, Marbach P, Mousson R. Salmon calcitonin binding sites in rat pituitary. Brain Res 1983; 261: 346–348.

    Article  PubMed  CAS  Google Scholar 

  94. Fischer JA, Tobler PH, Kaufmann M, et al. Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci USA 1981; 78: 7801–7805.

    Article  PubMed  CAS  Google Scholar 

  95. Gennari C, Avioli LV. Calcitoninh therapy in osteoporosis. In: Avioli LV, ed. The Osteoporotic Syndrome. Grune and Stratton, Orlando, 1987; 121–142.

    Google Scholar 

  96. Gennari C, Chierichetti SM, Gonnelli S, et al. Migraine prophylaxis with salmon calcitonin: a crossover double-blind, placebo-controlled study. Headache 1986; 26: 13–16.

    Article  PubMed  CAS  Google Scholar 

  97. Micieli G, Cavallini A, Martignoni E, et al. Effectiveness of salmon calcitonin nasal spray preparation in migraine treatment. Headache 1988; 28: 196–200.

    Article  PubMed  CAS  Google Scholar 

  98. Jaeger H, Maier C. Calcitonin in phantom limb pain: a double-blind study. Pain 1992; 48: 21–27.

    Article  PubMed  CAS  Google Scholar 

  99. Kessel C, Worz R. Immediate response of phantom limb pain to calcitonin. Pain 1987; 30: 79–87.

    Article  PubMed  CAS  Google Scholar 

  100. Eskola A, Pohjolainen T, Alaranta H, et al. Calcitonin treatment in lumbar spine stenosis: a randomized, placebo-controlled, double-blind, cross-over study with one-year follow-up. Calcif Tissue Int 1992; 50: 400–403.

    Article  PubMed  CAS  Google Scholar 

  101. Gennari C, Chierichetti SM, Piolini M, et al. Anlgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 1985; 38: 298–308.

    Google Scholar 

  102. Szanto J, Jozsef S, Rado J, et al. Pain killing with calcitonin in patients with malignant tumours. Oncology 1986; 43: 69–72.

    Article  PubMed  CAS  Google Scholar 

  103. Roth A, Kolaric K. Anlgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study. Oncology 1986; 43: 283–287.

    Article  PubMed  CAS  Google Scholar 

  104. Szanto J, Ady N, Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology 1992; 49: 180–182.

    Article  PubMed  CAS  Google Scholar 

  105. Braga PC. Calcitonin and its antinociceptive activity: animal and human investigations 1975–1992. Agents Action 1994; 41: 121–131.

    Article  CAS  Google Scholar 

  106. Miralles FS, Lopez-Soriano F, Puig MM, et al. Postoperative analgesia induced by sub-arachnoid lidocaine plus calcitonin. Anesth Analg 1987; 66: 615–618.

    Article  PubMed  CAS  Google Scholar 

  107. Martin MI, Goicoechea C, Colado MI et al. Anlgesic effect of salmon calcitonin administered by two routes. Effect on morphine analgesia. Eur J Pharmacol 1992; 224: 77–82.

    Article  PubMed  CAS  Google Scholar 

  108. Laurian L, Oberman Z, Graf E, et al. Calcitonin-induced increase in ACTH, beta-endorphin and cortisone secretion. Horm Metab Res 1986; 18: 268–271.

    Article  PubMed  CAS  Google Scholar 

  109. Franceschini R, Cataldi A, Barreca T et al. Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin. Eur J Pharmacol 1989; 37: 341–343.

    Article  CAS  Google Scholar 

  110. Rohner J, Planche D. Mechanism of the analgesic effect of calcitonin evidence for a twofold effect: morphine-like and cortisone-like. Clin Rheumatol 1985; 4: 218, 219.

    Google Scholar 

  111. Lundblad JR, Roberts JL. Regulation of proopiomelanocortin gene expression in pituitary. Endocr Rev 1988; 9: 135–158.

    Article  PubMed  CAS  Google Scholar 

  112. Shah GV, Wang W, Grosvernor CE, et al. Calcitonin inhibits basal and thyrotropin-releasing hormone-induced release of prolactin from anterior pituitary cells: evidence for a selective action exerted proximal to segretagogue-induced increases in cytosolic Ca2+. Endocrinology 1990; 127: 622–629.

    Google Scholar 

  113. Colado MI, Oramazabal MJ, Goicoechea C et al. Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse. Eur J Pharmacol 1994; 252: 291–297.

    Article  PubMed  CAS  Google Scholar 

  114. Welch SP, Olson KG. Salmon calcitonin-induced modulation of free intracellular calcium. Pharmacol Biochem Behav 1991; 39: 641–648.

    Article  PubMed  CAS  Google Scholar 

  115. Fiore CE, Castorina F, Malatino LS, et al. Antalgic activity of calcitonin: effectiveness of the epidural and subarachnoid routes in man. Int J Clin Pharm Res 1983; 3: 257–260.

    CAS  Google Scholar 

  116. Fraioli F, Fabbri A, Gnessi L, et al. Subarachnoid injection of salmon calcitonin induces analgesia in man. Eur J Pharmacol 1982; 78: 381, 382.

    Google Scholar 

  117. Pecile A, Ferri S, Braga PC, et al. Effects of intracerebroventricular calcitonin in the conscious rabbit. Experientia 1975; 31: 332, 333.

    Google Scholar 

  118. Braga PC, Ferri S, Santagostino A, et al. Lack of opiate receptor involvement in centrally induced calcitonin analgesia. Life Sci 1978; 22: 971–978.

    Article  PubMed  CAS  Google Scholar 

  119. Ceserani R, Colombo M, Olgiati V, et al. Calcitonin and prostaglandin system. Life Sci 1979; 25: 1851–1856.

    Article  PubMed  CAS  Google Scholar 

  120. Guidobono F, Netti C, Villani P, et al. Antinociceptive activity of eel calcitonin, injected into the inflamed paw in rats. Neuropharmacology 1991; 30: 1275–1278.

    Article  PubMed  CAS  Google Scholar 

  121. Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteporosis. Calcif Tissue Int 1991; 49: 59–13.

    Article  Google Scholar 

  122. Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue In 1991; 49: 369–372.

    Article  CAS  Google Scholar 

  123. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989; 11: 205–209.

    PubMed  CAS  Google Scholar 

  124. Pontiroli AE, Pajetta E, Scaglia L et al. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study. Aging Clin Exp Res 1994; 6: 459–463.

    CAS  Google Scholar 

  125. Combe B, Chen C, Aubin F. Equivalence of nasal spray and subcutaneous formulation of salmon calcitonin. Calcif Tissue Int 1997; 61: 10–15.

    Article  PubMed  CAS  Google Scholar 

  126. Gennari C, Passeri M, Chierichetti SM, et al. Side-effects of synthetic salmon and human calcitonin. Lancet 1983; 1: 594–595.

    Article  PubMed  CAS  Google Scholar 

  127. Wimalawansa SJ. Long-and short-term side effects and safety of calcitonin in man: a prospective study. Calcif Tissue Int 1993; 52: 90–93.

    Article  PubMed  CAS  Google Scholar 

  128. Thamsborg G, Storm TL, Sykulski R, et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif. Tissue Int. 1991; 48: 302–307.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Carlo Gennari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oregon Health & Science University, Portland, OR, USA

    Eric S. Orwoll MD  & Michael Bliziotes MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gennari, C. (2003). Basic Aspects of Calcitonin in Skeletal Health. In: Orwoll, E.S., Bliziotes, M. (eds) Osteoporosis. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-278-4_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-278-4_20

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-260-5

  • Online ISBN: 978-1-59259-278-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation